Risk factors for oligodendroglial tumors: A pooled international study

Neuro-Oncology

Volumn 13, Issue 2, 2011, Pages 242-250

  McCarthy, Bridget J ^a   Rankin, Kristin M ^a   Aldape, Ken ^b   Bondy, Melissa L ^b   Brännström, Thomas ^c   Broholm, Helle ^d   Feychting, Maria ^e   Il'Yasova, Dora ^f   Inskip, Peter D ^g   Johansen, Christoffer ^h   Melin, Beatrice S ^c   Ruder, Avima M ⁱ   Butler, Mary Ann ⁱ   Scheurer, Michael E ^j   Schüz, Joachim ^h   Schwartzbaum, Judith A ^k   Wrensch, Margaret R ^l   Davis, Faith G ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UMEÅ UNIVERSITY   (Sweden)

^d Rigshospitalet   (Denmark)

^e KAROLINSKA INSTITUTE   (Sweden)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g NATIONAL CANCER INSTITUTE   (United States)

^h INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

ⁱ NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

^j BAYLOR COLLEGE OF MEDICINE   (United States)

^k OHIO STATE UNIVERSITY   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Anaplastic oligodendroglioma; Epidemiology, mixed glioma, oligodendroglioma; Risk factors

Indexed keywords

ADULT; AGED; ALLERGY; ANAPLASTIC OLIGODENDROGLIOMA; ARTICLE; ASTHMA; CASE CONTROL STUDY; CLINICAL ASSESSMENT; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIXED GLIOMA; OLIGODENDROGLIOMA; RISK FACTOR; SCANDINAVIA; UNITED STATES;

ADULT; BRAIN NEOPLASMS; CASE-CONTROL STUDIES; DENMARK; FEMALE; HUMANS; INTERNATIONAL AGENCIES; MALE; META-ANALYSIS AS TOPIC; MIDDLE AGED; OLIGODENDROGLIOMA; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; SWEDEN; UNITED STATES;

EID: 79951848607     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/noq173     Document Type: Article

References (44)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds. WHO Classification of Tumours of the Central Nervous System. Lyon, France: IARC; 2007:53-68.
2. CBTRUS: Statistical Report: Primary Brain Tumors in the United States, 2000-2004. Hinsdale, IL: Published by the Central Brain Tumor Registry of the United States; 2008.
3. Nielsen MS, Christensen HC, Kosteljanetz M, Johansen C. Incidence of and survival from oligodendroglioma in Denmark, 1943-2002. Neuro-Oncology. 2009;11:311-317.
4. Lönn S, Klaeboe L, Hall P, et al. Incidence trends of adult primary intra-cerebral tumors in four Nordic countries. Int J Cancer. 2004;108:450-455. (Pubitemid 37549612)
5. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol. 2005;64:479-489. (Pubitemid 40781150)
6. Jenkins RB, Blair H, Ballman KV, et al. A t (1;19) (q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res. 2006;66:9852-9861. (Pubitemid 44672036)
7. Griffin CA, Burger P, Morsberger L, et al. Identification of der (1;19) (q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol. 2006;65:988-994. (Pubitemid 44521799)
8. Cairncross G, Jenkins R. Gliomas With 1p/19q Codeletion: a.k.a. Oligodendroglioma Cancer J. 2008;14:352-357.
9. Giannini C, Burger PC, Berkey BA, et al. Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathol. 2008;18:360-369. (Pubitemid 351782844)
10. Cairncross G, Macdonald D, Ludwin S, et al. Chemotherapy for ana-plastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1994;12:2013-2021.
11. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oli-godendrogliomas. J Natl Cancer Inst. 1998;90:1473-1479. (Pubitemid 28482012)
12. Smith JS, Perry A, Borell TJ, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol. 2000;18:636-645. (Pubitemid 30078545)
13. Bauman GS, Ino Y, Ueki K, et al. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys. 2000;48:825-830.
14. Bondy ML, Scheurer ME, Malmer B, et al. Brain Tumor Epidemiology Consortium. Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer. 2008;113(7 Suppl):1953-1968.
15. Inskip PD, Hatch EE, Stewart PA, et al. Study design for a case-control investigation of cellular telephones and other risk factors for brain tumors in adults. Radiat Prot Dosim. 1999;86:45-52. (Pubitemid 29446125)
16. Ruder AM, Waters MA, Carreón T, et al. The Brain Cancer Collaborative Study Group. The Upper Midwest Health Study: a case-control study of primary intracranial gliomas in farm and rural residents. J Agric Saf Health. 2006;12:255-274. (Pubitemid 44651027)
17. Wiemels JL, Wiencke JK, Sison JD, Miike R, McMillan A, Wrensch M. History of allergies among adults with glioma and controls. Int J Cancer. 2002;98:609-615. (Pubitemid 34208564)
18. Wrensch M, Lee M, Miike R, et al. Familial and personal medical history of cancer and nervous system conditions among adults with glioma and controls. Am J Epidemiol. 1997;145:581-593. (Pubitemid 27154860)
19. Rankin KM, Rauscher GH, McCarthy B, et al. Comparing the reliability of responses to telephone-administered versus self-administered Web-based surveys in a case-control study of adult malignant brain cancer. Cancer Epidemiol Biomarkers Prev. 2008;17:2639-2646.
20. Scheurer ME, El-Zein R, Thompson PA, et al. Long-term anti-inflammatory and antihistamine medication use and adult glioma risk. Cancer Epidemiol Biomarkers Prev. 2008;17:1277-1281.
21. Wigertz A, Lönn S, Schwartzbaum J, et al. Allergic conditions and brain tumor risk. Am J Epidemiol. 2007;166:941-950. (Pubitemid 47511691)
22. Fritz AG. World Health Organization. International Classification of Diseases for Oncology: ICD-O. 3rd ed. Geneva: World Health Organization; 2000.
23. SAS System software. Release 9.1.3. Cary, NC: SAS Institute Inc; 2007.
24. Benson VS, Pirie K, Green J, Casabonne D, Beral V; Million Women Study Collaborators. Lifestyle factors and primary glioma and menin-gioma tumours in the Million Women Study cohort. Br J Cancer. 2008;99:185-190.
25. Ahlbom A, Feychting M, Green A, Kheifets L, Savitz DA, Swerdlow AJ. Epidemiologic evidence on mobile phones and tumour risk: a review. Epidemiology. 2009;20:639-652.
26. Felini MJ, Olshan AF, Schroeder JC, et al. Reproductive factors and hormone use and risk of adult gliomas. Cancer Causes Control. 2009;20:87-96.
27. Lönn S, Rothman N, Shapiro WR, et al. Genetic variation in insulin-like growth factors and brain tumor risk. Neuro Oncol. 2008;10:553-559.
28. Samanic CM, De Roos AJ, Stewart PA, Rajaraman P, Waters MA, Inskip PD. Occupational exposure to pesticides and risk of adult brain tumors. Am J Epidemiol. 2008;167:976-985. (Pubitemid 351521740)
29. Lahkola A, Auvinen A, Raitanen J, et al. Mobile phone use and risk of glioma in 5 North European countries. Int J Cancer. 2007;120:1769-1775. (Pubitemid 46399364)
30. Wigertz A, Lönn S, Hall P, et al. Reproductive factors and risk of menin-gioma and glioma. Cancer Epidemiol Biomarkers Prev. 2008;17:2663-2670.
31. Zhou K, Liu Y, Zhang H, et al. XRCC3 haplotypes and risk of gliomas in a Chinese population: a hospital-based case-control study. Int J Cancer. 2009;124:2948-2953.
32. Ron E, Modan B, Boice JD Jr, et al. Tumors of the brain and nervous system after radiotherapy in childhood. N Engl J Med. 1988;319:1033-1039.
33. Yonehara S, Brenner AV, Kishikawa M, et al. Clinical and epidemiologic characteristics of first primary tumors of the central nervous system and related organs among atomic bomb survivors in Hiroshima and Nagasaki, 1958-1995. Cancer. 2004;101:1644-1654. (Pubitemid 39318913)
34. Shete S, Hosking FJ, Robertson LB, et al. Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet. 2009;41:899-904.
35. Wrensch M, Jenkins RB, Chang JS, et al. Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat Genet. 2009;41:905-908.
36. Terry MB, Howe G, Pogoda JM, et al. An international case-control study of adult diet and brain tumor risk: a histology-specific analysis by food group. Ann Epidemiol. 2009;19:161-171.
37. Liu Y, Scheurer ME, El-Zein R, et al. Association and interactions between DNA repair gene polymorphisms and adult glioma. Cancer Epidemiol Biomarkers Prev. 2009;18:204-214.
38. Linos E, Raine T, Alonso A, Michaud D. Atopy and risk of brain tumors: a meta-analysis. J Natl Cancer Inst. 2007;99:1544-1550. (Pubitemid 351767237)
39. Il'yasova D, McCarthy BJ, Marcello J, et al. Association between glioma and history of allergies, asthma, and eczema: a case-control study with three groups of controls. Cancer Epidemiol Biomarkers Prev. 2009;18:1232-1238.
40. Schwartzbaum J, Jonsson F, Ahlbom A, et al. Cohort studies of association between self-reported allergic conditions, immune-related diagnoses and glioma and meningioma risk. Int J Cancer. 2003;106:423-428. (Pubitemid 36870407)
41. Cairncross G, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oli-godendrogliomas. J Natl Cancer Inst. 1998;90:1473-1479. (Pubitemid 28482012)
42. Aldape K, Burger PC, Perry A. Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. Arch Pathol Lab Med. 2007;131:242-251.
43. McCarthy BJ, Propp JM, Davis FG, Burger PC. Time Trends in Oligodendroglial and Astrocytic Tumor Incidence. Neuroepidemiology. 2008;30:34-44. (Pubitemid 351311724)
44. Burger PC, Minn AY, Smith JS, et al. Losses of chromosomal arms 1p and 19q in the diagnosis of oligodendroglioma. A study of paraffin-embedded sections. Mod Pathol. 2001;14:842-853. (Pubitemid 32889241)